VRNA

Verona Pharma plc Sponsored ADR · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website veronapharma.com
Employees(FY) 35
ISIN US9250501064

Performance

-0.38%

+12.19%

+40.66%

+198.85%

+95.42%

YTD

+163.75%

Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

Advanced Technical Analysis

Technical Analysis of VRNA 2024-11-20

The stock exhibits a strong bullish sentiment with a Moving Average Score of 96, indicating robust upward momentum, while the Technical Score of 73 further supports this positive outlook. However, the Oscillators Score of 50 suggests a neutral stance, indicating potential consolidation or indecision in the short term.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of VRNA

Stock Rank

Recent News & Updates

2024-11-19 02:00
Verona Pharma Announces December 2024 Investor Conference Participation(GlobeNewswire)
2024-11-18 13:00
Verona Pharma Announces December 2024 Investor Conference Participation(Globenewswire)
2024-11-06 18:00
Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance(Businesswire)
2024-11-05 17:48
Verona Pharma Insider Sold Shares Worth $568,387, According to a Recent SEC Filing(MT Newswires)
2024-11-05 17:47
Verona Pharma Insider Sold Shares Worth $618,658, According to a Recent SEC Filing(MT Newswires)
2024-11-05 05:15
Verona Pharma (NASDAQ:VRNA) shareholder returns have been incredible, earning 724% in 5 years(Simply Wall St.)
2024-11-05 02:03
Verona Pharma PLC (VRNA) Q3 2024 Earnings Call Highlights: Strong Ohtuvayre Launch Amid Rising Costs(GuruFocus.com)
2024-11-05 02:00
Verona Pharma to Present at Jefferies London Healthcare Conference(GlobeNewswire)
2024-11-04 13:00
Verona Pharma to Present at Jefferies London Healthcare Conference(Globenewswire)
2024-11-04 03:22
Verona Pharma's Q3 Loss Widens(MT Newswires)
2024-11-04 02:00
Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update(GlobeNewswire)
2024-11-03 13:00
Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update(Globenewswire)
2024-10-31 21:03
Verona Pharma PLC (VRNA) Q3 2024 Earnings Report Preview: What To Expect(Yahoo Finance)
2024-10-25 08:50
Recent Price Trend in Verona Pharma (VRNA) is Your Friend, Here's Why(Zacks)
2024-10-25 04:59
Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma(Zacks)
2024-10-24 09:06
5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright(Zacks)
2024-10-23 03:19
Verona Pharma Insider Sold Shares Worth $2,253,237, According to a Recent SEC Filing(MT Newswires)
2024-10-23 03:17
Verona Pharma Insider Sold Shares Worth $2,303,773, According to a Recent SEC Filing(MT Newswires)
2024-10-21 02:00
Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update(GlobeNewswire)
2024-10-20 14:00
Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update(Globenewswire)
2024-10-11 09:55
Wall Street Analysts Think Verona Pharma (VRNA) Could Surge 25.25%: Read This Before Placing a Bet(Zacks)
2024-10-09 08:50
Verona Pharma (VRNA) Is a Great Choice for 'Trend' Investors, Here's Why(Zacks)
2024-10-03 08:08
Wells Fargo Initiates Verona Pharma at Overweight With $50 Price Target(MT Newswires)
2024-09-30 02:00
Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024(GlobeNewswire)
2024-09-29 14:00
Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024(Globenewswire)
2024-09-16 20:29
Ritedose is Proud to Partner with Verona Pharma to Deliver First-In-Class COPD Drug, Ohtuvayre (ensifentrine)*(Prnewswire)
2024-09-14 01:52
Insider Sale: CFO Mark Hahn Sells 600,000 Shares of Verona Pharma PLC (VRNA)(GuruFocus.com)
2024-09-14 01:51
Verona Pharma PLC (VRNA) CEO David Zaccardelli Sells 600,000 Shares(GuruFocus.com)
2024-09-05 02:00
Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024(GlobeNewswire)
2024-09-04 14:00
Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024(Globenewswire)

Page 1 of 7

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.